Autoantibodies to Abl and Bcr proteins

M. Talpaz, X. Qiu, K. Cheng, J. E. Cortes, H. Kantarjian, R. Kurzrock

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Formation of an aberrant, chimeric Bcr-Abl protein is the hallmark of Philadelphia (Ph) chromosome-positive leukemias. The Bcr-Abl protein, as well as its normal cellular counterparts - Abl and Bcr - are intracellular molecules with postulated roles in a variety of critical biologic functions. In this study, we demonstrate the existence of autoantibodies against these proteins. Plasma from 18 of 31 individuals (58%), including 14 of 20 Ph-positive CML patients (70%), two of four normal volunteers (50%), and two of seven patients with Ph-negative leukemia (29%) recognized p210(Bcr-Abl) when used in immunoprecipitation followed by immunoblotting experiments. In all 18 patients, plasma was able to recognize baculovirus-expressed Abl protein; in four patients, recognition of baculovirus-expressed Bcr protein was also demonstrated. These observations suggest that a humoral immune response to p210(Bcr-Abl) is discernible in both Ph-positive and -negative leukemias and in healthy individuals, and is most likely due to autoantibodies which recognize normal Abl and, to a lesser extent, normal Bcr proteins.

Original languageEnglish (US)
Pages (from-to)1661-1666
Number of pages6
JournalLeukemia
Volume14
Issue number9
StatePublished - Jan 1 2000
Externally publishedYes

Keywords

  • Abl
  • Antibody
  • Bcr
  • Chronic myelogenous leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Autoantibodies to Abl and Bcr proteins'. Together they form a unique fingerprint.

  • Cite this

    Talpaz, M., Qiu, X., Cheng, K., Cortes, J. E., Kantarjian, H., & Kurzrock, R. (2000). Autoantibodies to Abl and Bcr proteins. Leukemia, 14(9), 1661-1666.